Abstract: Provided herein are dynamic adaptive scheduling (DAS) systems. In some embodiments, the DAS systems include a first scheduler, a second scheduler that is slower than the first scheduler, and a runtime preselection classifier that is operably connected to the first scheduler and the second scheduler, which runtime preselection classifier is configured to effect selective use of the first scheduler or the second scheduler to perform a given scheduling task. Related systems, computer readable media, and additional methods are also provided.
Type:
Application
Filed:
September 19, 2023
Publication date:
March 28, 2024
Applicants:
ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY, WISCONSIN ALUMNI RESEARCH FOUNDATION, UNIVERSITY OF ARIZONA, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Inventors:
Chaitali CHAKRABARTI, Umit OGRAS, Ahmet GOKSOY, Anish KRISHNAKUMAR, Ali AKOGLU, Md Sahil HASSAN, Radu MARCULESCU, Allen-Jasmin FARCAS
Abstract: Immunogenic compositions comprising viral vectors and surfactants are provided. Methods for administration and preparation of such compositions are also provided.
Type:
Application
Filed:
September 27, 2023
Publication date:
March 28, 2024
Applicant:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Abstract: The present disclosure is directed to human antibodies binding to and neutralizing ebolavirus and methods for use thereof. A further embodiment involves a monoclonal antibody, wherein the antibody or antibody fragment is characterized by clone-paired heavy and light chain CDR sequences. In yet another embodiment, there is provided a hybridoma or engineered cell encoding an antibody or antibody fragment. An additional embodiment comprises a vaccine formulation comprising one or more antibodies or antibody fragments characterized by clone-paired heavy and light chain CDR sequences. In still a further embodiment, there is provided a method of protecting the health of a placenta and/or fetus of a pregnant a subject infected with or at risk of infection with ebolavirus comprising delivering to said subject the antibody or antibody fragment.
Type:
Grant
Filed:
July 11, 2019
Date of Patent:
March 26, 2024
Assignees:
VANDERBILT UNIVERSITY, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Inventors:
James E. Crowe, Jr., Pavlo Gilchuk, Alexander Bukreyev
Abstract: Orthosis device and related methods for controlling the device to counteract a gravitational force exerted on the person without directing the orthosis device in a pre-determined pattern of motion.
Type:
Grant
Filed:
December 8, 2016
Date of Patent:
March 26, 2024
Assignee:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Abstract: A magnetic tunnel junction is provided. The magnetic tunnel junction comprises an insulating tunnel barrier and a fixed ferromagnet layer adjacent the tunnel barrier. The fixed ferromagnet comprises a fixed magnetization along an easy axis approximately normal to an interface between the fixed ferromagnet and the tunnel barrier. A free ferromagnet layer is adjacent the tunnel barrier on the side opposite the fixed ferromagnet. The free ferromagnet layer comprises a bistable magnetization along the easy axis that can switch between a parallel state and an anti-parallel state with the fixed ferromagnet. A heavy metal layer is adjacent the free ferromagnet on the side opposite the tunnel barrier. A unidirectional electric current pulse through the heavy metal layer switches the bistable magnetization of the free ferromagnet, thereby switching an electrical resistance state of the magnetic tunnel junction.
Type:
Grant
Filed:
April 30, 2020
Date of Patent:
March 26, 2024
Assignee:
Board of Regents, The University of Texas System
Abstract: Disclosed herein are ACE2 recombinant proteins and methods of using such for therapeutic and/or diagnostic purposes. Also provided herein are methods for producing such recombinant proteins.
Type:
Application
Filed:
January 7, 2022
Publication date:
March 21, 2024
Applicant:
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Abstract: The present invention includes compositions and methods for treating an autoimmune disorder or a cancer in a subject in need thereof, the method comprising: administering an effective amount of a composition comprising an oligonucleotide that specifically binds a complementary sequence of the Interleukin-7 receptor (IL7R) pre-mRNA that influences splicing of exon 6, wherein the SM-ASO increases or decreases inclusion of exon 6 in IL7R pre-mRNAs and respectively decreases or increases expression of the soluble isoform of IL7R (sIL7R). In certain embodiments, the oligonucleotide is an antisense oligonucleotide (ASO), or a splice-modulating antisense oligonucleotide (SM-ASO).
Type:
Application
Filed:
November 6, 2023
Publication date:
March 21, 2024
Applicant:
Board of Regents, The University of Texas System
Inventors:
Mariano A. Garcia-Blanco, Gaddiel Galarza-Munoz, Shelton S. Bradrick
Abstract: Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids.
Type:
Application
Filed:
December 13, 2022
Publication date:
March 21, 2024
Applicant:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Abstract: Aspects of the present disclosure relate to systems and methods for analyzing a tumor, and more specifically, analyzing a tumor to identify a biological aggressiveness of the tumor. One example method for tumor analysis includes: receiving one or more input features associated with a geometric shape of a tumor, the one or more input features including at least a value indicating a circularity of the tumor; determining, via a machine learning component, a characteristic of the tumor based on the one or more input features, the characteristic being indicative of patient survivability; and outputting an indication of the characteristic.
Type:
Application
Filed:
September 18, 2023
Publication date:
March 21, 2024
Applicants:
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
Inventors:
Matteo Ligorio, Rebecca Napier, William Gasper, Dario Ghersi
Abstract: An apparatus for a heart of a patient having a cardiac assist device adapted to be implanted into the patient to assist the heart with pumping blood. The apparatus has a sensor adapted to be implanted into the patient. The sensor in communication with the cardiac assist device and the heart which measures native volume of the heart. Alternatively, the sensor monitors the heart based on admittance while the cardiac assist device. Alternatively, the sensor monitors the heart based on impedance.
Type:
Grant
Filed:
April 22, 2021
Date of Patent:
March 19, 2024
Assignees:
Board of Regents, The University of Texas System, CardioVol, LLC
Inventors:
John Porterfield, Jonathan W. Valvano, Clay Heighten, Anil Kottam, Marc David Feldman, Aleksandra Borisovna Gruslova, Drew R. Nolen
Abstract: The current disclosure describes effective therapeutic treatments and diagnostic/prognostic methods for colorectal cancer based on the expression or activity level of biomarkers. Aspects of the disclosure relate to a method for treating a subject for colorectal cancer, the method comprising treating the subject for colorectal cancer after the expression level of one or more biomarker genes from Table 1, Table 2, Table 3, Table 4, Table 5, Table S2, Table S3, Table S4, Table S5, FIG. 4A, and/or FIG. 4B has been determined in a sample from the subject.
Type:
Application
Filed:
February 22, 2022
Publication date:
March 14, 2024
Applicant:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Abstract: Chronic tobacco smoke exposure (TSE)-induced lung injury includes increased alveolar and airway inflammation, type II alveolar epithelial cells (A2Cs) senescence and apoptosis, and mucus hypersecretion by airway epithelial cells (AECs) that can be treated by the caveolin-1 peptide CSP7 (SEQ ID NO:1). Caveolin-1 and p53 mediated induction of plasminogen activator inhibitor-1 (PAI-1) expression by interleukin 17A, TSE, pollution and other causes leads to lung injury, which can be abrogated by CSP7 treatment, which abolishes A2Cs senescence and apoptosis and AEC mucus hypersecretion. CSP7 treatment of lung tissue of patients with TSE-induced lung injury decreases A2C apoptosis and AEC mucus hypersecretion. Lung injury with A2Cs senescence and apoptosis and AEC mucus hypersecretion caused by TSE-induced PAI-1 expression in lung tissue of patients is abolished by CSP7.
Type:
Application
Filed:
October 25, 2023
Publication date:
March 14, 2024
Applicant:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Abstract: Modular dendrimers with cationic groups and lipophilic groups are provided herein. In some aspects, the dendrimers provided herein may be formulated in compositions which contain a nucleic acid and one or more helper excipients. In some aspects, these compositions may also be used to treat diseases or disorders with a therapeutic nucleic acid.
Type:
Application
Filed:
November 13, 2023
Publication date:
March 14, 2024
Applicant:
The Board of Regents of The University of Texas System
Abstract: The present disclosure provides ?2?-1 C-terminal domain mimetics for the treatment of pain, epilepsy or other disorders in a subject. Further provided is an ?2?-1 C-terminal domain peptide which blocks binding of ?2?-1 to the glutamate receptors NMDAR and AMPAR.
Type:
Application
Filed:
September 11, 2023
Publication date:
March 14, 2024
Applicant:
Board of Regents, The University of Texas System
Abstract: The present disclosure concerns methods and compositions related to adoptive cell therapy and its efficacy related to the gut microbiome. In specific cases, it may be determined for an individual whether or not a chimeric antigen receptor (CAR) T-cell therapy will be effective for an individual based on their gut microbiome. An individual may be provided a composition comprising one or more particular microbe compositions based on analysis of the gut microbiome of the individual and prior to administration of CAR T-cell therapy, in specific embodiments.
Type:
Application
Filed:
January 28, 2022
Publication date:
March 14, 2024
Applicant:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Inventors:
Neeraji Saini, Chia-Chi Chang, Robert R. Jenq, Sattva S. Neelapu
Abstract: Methods for diagnosis and treatment of cancers by use of exosomes comprising miRNAs and precursors thereof. For example, in some aspects, a cancer may be diagnosed or evaluated by determining the miRNA content of exosomes in a sample from a subject or by detecting miRNA processing in exosomes.
Type:
Grant
Filed:
March 23, 2020
Date of Patent:
March 12, 2024
Assignees:
Board of Regents, The University of Texas System, Beth Israel Deaconess Medical Center, Inc.
Abstract: The present disclosure provides a method of preventing, treating, or inhibiting migraine in a subject, by administering to the subject an amount of first therapeutic selected from cercosporamide, eFT508, or 4EGI-1 sufficient to prevent, treat, or inhibit said migraine. The present disclosure further provides a composition including at least two of cercosporamide. eFT508, or 4EGI-1, both in an amount sufficient to prevent, treat, or inhibit migraine in a subject and a pharmaceutically acceptable carrier. The present disclosure further provides a composition including at least one of cercosporamide, eFT508, or 4EGI-1 and at least one additional migraine therapeutic, both in an amount sufficient to prevent, treat, or inhibit migraine in a subject, and a pharmaceutically acceptable carrier.
Type:
Grant
Filed:
October 7, 2021
Date of Patent:
March 12, 2024
Assignee:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Abstract: The invention provides for novel glaucoma surgical devices comprising a microfluidic meshwork. The meshwork comprises interconnected, cellular-dimensioned microfluidic channels. Excess fluid in the eye can be drained and diffused through the microfluidic channels. The meshwork is porous and highly flexible, affording mechanical compliance similar to that of eye tissue. The meshwork minimizes foreign body reactions to the implant, decreasing fibrosis and capsule formation.
Type:
Grant
Filed:
February 22, 2018
Date of Patent:
March 12, 2024
Assignee:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Abstract: The present disclosure is directed to methods and compositions for the prediction and treatment of immunotherapy-induced toxicities, as well as improved methods for the treatment of cancer with immunotherapies.
Type:
Application
Filed:
June 21, 2023
Publication date:
March 7, 2024
Applicant:
The Board of Regents of The University of Texas System
Inventors:
David E. Gerber, Edward Wakeland, Quan Li, Saad Khan, Jason Y. Park, Xin Luo, Yang Xie